NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1973.60 -7.70 (-0.39%)

779.1K NSE+BSE Volume

NSE 03 Oct, 2025 3:31 PM (IST)

90,145.7

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

14 Dec 2021

1973.60

-0.39%

USFDA regulatory hurdle crossed at Goa

Neutral: Lupin Ltd.

Target

Motilal Oswal

Learnings at Goa to enhance remediation measures at other sites as well After almost 4.5 years of regulatory hurdles, LPC received a favorable classification (Voluntary Action Indicated or VAI) for its Goa facility from the USFDA. This is a big relief from a compliance standpoint, given the reasonable contribution in the base business as well as double digit ANDAs pending approval from the Goa site. We expect 21% earnings CAGR over FY21-23E and raise our 12-month forward P/E to 25x (to factor Goa compliance) from 24x earlier and arrive at our TP to INR990/share. While the regulatory clearance removes a key overhang on the Goa...

Lupin Ltd. is trading below its 150 day SMA of 1978.6

Lupin Ltd.

14 Dec 2021

1973.60

-0.39%

Lupin Ltd

Hold: Lupin Ltd.

ICICI Securities Limited

About the stock: Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories....

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

08 Nov 2021

1973.60

-0.39%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company specializes in branded and generic formulations, API's and advanced drug delivery systems in the area of biotechnology. The...

Lupin Ltd. is trading below its 150 day SMA of 1978.6

Lupin Ltd.

29 Oct 2021

1973.60

-0.39%

Q2FY22 Result Update - On the path of gradual recovery - ACCUMULATE

Accumulate: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Lupin's (LPC) H1 profitability was soft on account of low US sales and weak GMs. We believe recovery in US sales will be gradual and may hinge on market share gains in gAlbuterol with timely niche launches. Also, strong inhalation pipeline and biosimilar franchise provides visibility beyond FY22. Further, margins will improve in H2FY22/FY23 with likely savings in promotional expenses related to Solosec and rationalization of R&D expenses. We expect 21% EPS CAGR over FY21-24E and recommend Accumulate' with TP of Rs 1,004/share, 23x Sept 2023E EPS....

Lupin Ltd. is trading above its 100 day SMA of 1960.5

Lupin Ltd.

29 Oct 2021

1973.60

-0.39%

Market share gain/cost saving steps to drive profitability

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered an in-line 2QFY22 operational performance, led by a healthy double-digit growth in Domestic Formulations (DF) and stable US sales. The company has restructured its US specialty business by taking extensive cost measures. In addition to better sales prospects in DF/US, the cost saving steps will enhance its profitability, going forward. We cut our FY22E/FY23E EPS estimates by 5%/4% to factor in: a) lower API sales, b) slower growth in Europe (EMEA), c) reduced operating leverage, and b) higher raw material costs. We value LPC at 24x 12M forward earnings...

Lupin Ltd. is trading below its 150 day SMA of 1978.6

Lupin Ltd.

29 Oct 2021

1973.60

-0.39%

Lupin Ltd

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

12 Aug 2021

1973.60

-0.39%

Lupin Ltd

Hold: Lupin Ltd.

Target

ICICI Securities Limited

...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

12 Aug 2021

1973.60

-0.39%

Q1FY22 Result Update - Miss on all counts; Competitive pressure and lack of visibility drives downgrade - REDUCE

Sell: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Tax rate guided at 27-28% from 30% in FY22E. We see a near term challenging period for Lupin (LPC) and downgrade our recommendation to REDUCE' from Accumulate' due to delay in resolution of two key plants (Goa and Indore unit-2) as more than 50% of pending ANDAs...